These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 27824902)

  • 1. Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis.
    Lian XY; Zhang ZH; Deng ZQ; He PF; Yao DM; Xu ZJ; Wen XM; Yang L; Lin J; Qian J
    PLoS One; 2016; 11(11):e0165948. PubMed ID: 27824902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
    Jonasova A; Bokorova R; Polak J; Vostry M; Kostecka A; Hajkova H; Neuwirtova R; Siskova M; Sponerova D; Cermak J; Mikulenkova D; Cervinek L; Brezinova J; Michalova K; Fuchs O
    Eur J Haematol; 2015 Jul; 95(1):27-34. PubMed ID: 25284710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.
    Syed YY; Scott LJ
    Drugs; 2013 Jul; 73(11):1183-96. PubMed ID: 23824699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
    Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.
    Komrokji RS; List AF
    Ann Oncol; 2016 Jan; 27(1):62-8. PubMed ID: 26504152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.
    Oliva EN; Lauseker M; Aloe Spiriti MA; Poloni A; Cortelezzi A; Palumbo GA; Balleari E; Sanpaolo G; Volpe A; Ricco A; Ronco F; Alati C; D'Errigo MG; Santacaterina I; Kündgen A; Germing U; Latagliata R
    Cancer Med; 2015 Dec; 4(12):1789-97. PubMed ID: 26376955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
    Cerqui E; Pelizzari A; Schieppati F; Borlenghi E; Pagani C; Bellotti D; Lamorgese C; Boiocchi L; Sottini A; Imberti L; Rossi G
    Leuk Lymphoma; 2015; 56(11):3129-34. PubMed ID: 25811676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.
    Merkerova MD; Krejcik Z; Belickova M; Hrustincova A; Klema J; Stara E; Zemanova Z; Michalova K; Cermak J; Jonasova A
    Eur J Haematol; 2015 Jul; 95(1):35-43. PubMed ID: 25287904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
    Sánchez-García J; Del Cañizo C; Lorenzo I; Nomdedeu B; Luño E; de Paz R; Xicoy B; Valcárcel D; Brunet S; Marco-Betes V; García-Pintos M; Osorio S; Tormo M; Bailén A; Cerveró C; Ramos F; Diez-Campelo M; Such E; Arrizabalaga B; Azaceta G; Bargay J; Arilla MJ; Falantes J; Serrano-López J; Sanz GF;
    Br J Haematol; 2014 Jul; 166(2):189-201. PubMed ID: 24716538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythroid but not cytogenetic response in a case with 5q- syndrome: a delayed effect of lenalidomide or a consequence of deferasirox treatment?
    Vigna E; Recchia AG; Cuzzola M; Morabito L; Gentile M; Morabito F
    Leuk Lymphoma; 2014 Jun; 55(6):1408-9. PubMed ID: 23952245
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS).
    Raza A; Galili N; Mulford D; Smith SE; Brown GL; Steensma DP; Lyons RM; Boccia R; Sekeres MA; Garcia-Manero G; Mesa RA
    J Hematol Oncol; 2012 Apr; 5():18. PubMed ID: 22546242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
    Talati C; Sallman D; List A
    Semin Hematol; 2017 Jul; 54(3):159-166. PubMed ID: 28958290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q).
    Butrym A; Lech-Maranda E; Patkowska E; Kumiega B; Bieniaszewska M; Mital A; Madry K; Torosian T; Wichary R; Rybka J; Warzocha K; Mazur G
    BMC Cancer; 2015 Jul; 15():508. PubMed ID: 26152663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of lenalidomide in the treatment of myelodysplastic syndromes.
    Komrokji RS; List AF
    Semin Oncol; 2011 Oct; 38(5):648-57. PubMed ID: 21943671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).
    Fenaux P; Giagounidis A; Selleslag D; Beyne-Rauzy O; Mittelman M; Muus P; Nimer SD; Hellström-Lindberg E; Powell BL; Guerci-Bresler A; Sekeres MA; Deeg HJ; Del Cañizo C; Greenberg PL; Shammo JM; Skikne B; Yu X; List AF
    J Hematol Oncol; 2017 Jun; 10(1):131. PubMed ID: 28651604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.
    Kuendgen A; Lauseker M; List AF; Fenaux P; Giagounidis AA; Brandenburg NA; Backstrom J; Glasmacher A; Hasford J; Germing U;
    Leukemia; 2013 Apr; 27(5):1072-9. PubMed ID: 23257782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
    Stahl M; Zeidan AM
    Cancer; 2017 May; 123(10):1703-1713. PubMed ID: 28192601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide for treatment of myelodysplastic syndromes.
    Komrokji RS; List AF
    Curr Pharm Des; 2012; 18(22):3198-203. PubMed ID: 22571699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
    Giagounidis A; Mufti GJ; Fenaux P; Germing U; List A; MacBeth KJ
    Ann Hematol; 2014 Jan; 93(1):1-11. PubMed ID: 24018623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.